PT  - JOURNAL ARTICLE
AU  - El Moussaoui, R
AU  - Roede, B M
AU  - Speelman, P
AU  - Bresser, P
AU  - Prins, J M
AU  - Bossuyt, P M M
TI  - Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies
AID  - 10.1136/thx.2007.090613
DP  - 2008 May 01
TA  - Thorax
PG  - 415--422
VI  - 63
IP  - 5
4099  - http://thorax.bmj.com/content/63/5/415.short
4100  - http://thorax.bmj.com/content/63/5/415.full
SO  - Thorax2008 May 01; 63
AB  - Background: A study was undertaken to determine whether a short course of antibiotic treatment (⩽5 days) is as effective as the conventional longer treatment in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD).Methods: MEDLINE, EMBASE and the Cochrane central register of controlled trials were searched to July 2006. Studies considered eligible were double-blind randomised clinical trials including adult patients ⩾18 years of age with a clinical diagnosis of exacerbation of COPD or chronic bronchitis, no antimicrobial therapy at the time of diagnosis and random assignment to antibiotic treatment for ⩽5 days versus &amp;gt;5 days. The primary outcome measure was clinical cure at early follow-up on an intention-to-treat basis.Results: 21 studies with a total of 10 698 patients were included. The average quality of the studies was high: the mean (SD) Jadad score was 3.9 (0.9). At early follow-up (&amp;lt;25 days), the summary odds ratio (OR) for clinical cure with short treatment versus conventional treatment was 0.99 (95% CI 0.90 to 1.08). At late follow-up the summary OR was 1.0 (95% CI 0.91 to 1.10) and the summary OR for bacteriological cure was 1.05 (95% CI 0.87 to 1.26). Similar summary ORs were observed for early cure in trials with the same antibiotic in both arms and in studies grouped by the antibiotic class used in the short-course arm.Conclusions: A short course of antibiotic treatment is as effective as the traditional longer treatment in patients with mild to moderate exacerbations of chronic bronchitis and COPD.